These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 30241240)

  • 1. Outcomes in Treatment-Naïve Patients With Metastatic Extremity Osteosarcoma Treated With OGS-12, a Novel Non-High-Dose Methotrexate-Based, Dose-Dense Combination Chemotherapy, in a Tertiary Care Cancer Center.
    Bajpai J; Chandrasekharan A; Simha V; Talreja V; Karpe A; Pandey N; Singh A; Rekhi B; Vora T; Ghosh J; Banavali S; Gupta S
    J Glob Oncol; 2018 Sep; 4():1-10. PubMed ID: 30241240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes in non-metastatic treatment naive extremity osteosarcoma patients treated with a novel non-high dosemethotrexate-based, dose-dense combination chemotherapy regimen 'OGS-12'.
    Bajpai J; Chandrasekharan A; Talreja V; Simha V; Chandrakanth MV; Rekhi B; Khurana S; Khan A; Vora T; Ghosh J; Banavali SD; Gupta S
    Eur J Cancer; 2017 Nov; 85():49-58. PubMed ID: 28888849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteosarcoma journey over two decades in India: Small steps, big changes.
    Bajpai J; Chandrasekharan A; Simha V; Mandal T; Shah K; Hingmare S; Rangarajan B; Shetty N; Vora T; Ghosh J; Rekhi B; Banavali S; Gupta S
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27877. PubMed ID: 31207015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience.
    Choeyprasert W; Pakakasama S; Sirachainan N; Songdej D; Chuansumrit A; Anurathapan U; Hongeng S; Nartthanarung A
    Asian Pac J Cancer Prev; 2014; 15(22):9823-9. PubMed ID: 25520112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy for osteosarcoma of the extremities with synchronous lung metastases: treatment with cisplatin, adriamycin and high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Ferrari S; Saeter G; Donati D; Longhi A; Manfrini M; Bertoni F; Rimondini S; Monti C; Forni C
    Oncol Rep; 2000; 7(2):339-46. PubMed ID: 10671683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide.
    Bacci G; Briccoli A; Rocca M; Ferrari S; Donati D; Longhi A; Bertoni F; Bacchini P; Giacomini S; Forni C; Manfrini M; Galletti S
    Ann Oncol; 2003 Jul; 14(7):1126-34. PubMed ID: 12853357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pirarubicin versus doxorubicin in neoadjuvant/adjuvant chemotherapy for stage IIB limb high-grade osteosarcoma: does the analog matter?
    Yu W; Tang L; Lin F; Yao Y; Shen Z
    Med Oncol; 2015 Jan; 32(1):307. PubMed ID: 25432694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant chemotherapy with high-dose Ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups.
    Ferrari S; Smeland S; Mercuri M; Bertoni F; Longhi A; Ruggieri P; Alvegard TA; Picci P; Capanna R; Bernini G; Müller C; Tienghi A; Wiebe T; Comandone A; Böhling T; Del Prever AB; Brosjö O; Bacci G; Saeter G;
    J Clin Oncol; 2005 Dec; 23(34):8845-52. PubMed ID: 16246977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.
    Hung GY; Yen HJ; Yen CC; Chen WM; Chen PC; Wu HT; Chiou HJ; Chang WH; Hsu HE
    Ann Surg Oncol; 2015 Apr; 22(4):1080-7. PubMed ID: 25323470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients.
    Nataraj V; Rastogi S; Khan SA; Sharma MC; Agarwala S; Vishnubhatla S; Bakhshi S
    Clin Transl Oncol; 2016 Sep; 18(9):937-44. PubMed ID: 26742936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IAP Chemotherapy Regimen Is a Viable and Cost-effective Option in Children and Adolescents With Osteosarcoma: A Comparative Analysis With MAP Regimen on Toxicity and Survival.
    Verma P; Jain S; Kapoor G; Tripathi R; Sharma P; Doval DC
    J Pediatr Hematol Oncol; 2021 May; 43(4):e466-e471. PubMed ID: 32925402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of bone and soft-tissue sarcomas registered during the year 2012 at Tata Memorial Hospital, Mumbai, with clinical outcomes.
    Bajpai J; Khanna N; Vora T; Gulia A; Laskar S; Puri A; Sanduptla B; Chinnaswamy G; Nayak P; Juvekar SL; Janu A; Desai S; Ghosh J; Purandare N; Ramadwar M; Rangarajan V; Rekhi B
    Indian J Cancer; 2018; 55(1):37-44. PubMed ID: 30147091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonmetastatic osteosarcoma of the extremity. Neoadjuvant chemotherapy with methotrexate, cisplatin, doxorubicin and ifosfamide. An Italian Sarcoma Group study (ISG/OS-Oss).
    Ferrari S; Meazza C; Palmerini E; Tamburini A; Fagioli F; Cozza R; Ferraresi V; Bisogno G; Mascarin M; Cefalo G; Manfrini M; Capanna R; Biagini R; Donati D; Picci P
    Tumori; 2014; 100(6):612-9. PubMed ID: 25688494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developing a prognostic model for patients with localized osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate: A single-center experience of 237 patients.
    Nataraj V; Batra A; Rastogi S; Khan SA; Sharma MC; Vishnubhatla S; Bakhshi S
    J Surg Oncol; 2015 Nov; 112(6):662-8. PubMed ID: 26381138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate.
    Meyers PA; Schwartz CL; Krailo M; Kleinerman ES; Betcher D; Bernstein ML; Conrad E; Ferguson W; Gebhardt M; Goorin AM; Harris MB; Healey J; Huvos A; Link M; Montebello J; Nadel H; Nieder M; Sato J; Siegal G; Weiner M; Wells R; Wold L; Womer R; Grier H
    J Clin Oncol; 2005 Mar; 23(9):2004-11. PubMed ID: 15774791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children's Research Hospital OS99 trial.
    Daw NC; Neel MD; Rao BN; Billups CA; Wu J; Jenkins JJ; Quintana J; Luchtman-Jones L; Villarroel M; Santana VM
    Cancer; 2011 Jun; 117(12):2770-8. PubMed ID: 21656756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols.
    Kager L; Zoubek A; Pötschger U; Kastner U; Flege S; Kempf-Bielack B; Branscheid D; Kotz R; Salzer-Kuntschik M; Winkelmann W; Jundt G; Kabisch H; Reichardt P; Jürgens H; Gadner H; Bielack SS;
    J Clin Oncol; 2003 May; 21(10):2011-8. PubMed ID: 12743156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy.
    Ferrari S; Bacci G; Picci P; Mercuri M; Briccoli A; Pinto D; Gasbarrini A; Tienghi A; Brach del Prever A
    Ann Oncol; 1997 Aug; 8(8):765-71. PubMed ID: 9332684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly effective reduced toxicity dose-intensive pilot protocol for non-metastatic limb osteogenic sarcoma (SCOS 89).
    Shkalim-Zemer V; Ash S; Toledano H; Kollender Y; Issakov J; Yaniv I; Cohen IJ
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):909-16. PubMed ID: 26365289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of long-term outcome between doublet and triplet neoadjuvant chemotherapy in non-metastatic osteosarcoma of the extremity.
    Hong S; Shin SJ; Jung M; Jeong J; Lee YJ; Shin KH; Roh JK; Rha SY
    Oncology; 2011; 80(1-2):107-17. PubMed ID: 21677455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.